drugset / Trial / NCT04870164

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

NCT04870164

Phase 1 Terminated 53 enrolled Molecular Partners AG
RandomizedSequentialQuadruple-blindOther

Summary

This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers

Timeline

Start
2020-11-18
Primary completion
2022-01-06
Completion
2022-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ensovibep Protein / enzyme biologic Intravenous

Indications